![](https://investorshub.advfn.com/uicon/189332.png?cb=1465554763)
Tuesday, December 29, 2015 9:25:27 AM
Am still not sure if/when NNVC will see >$100/share - but suspect that if it does reach those lofty quantities it won't be for at least a few years. Just too much lost ground to be made up and not enough certainty of sufficient revenue sources to drive a gain to those levels (yet).
Am among those 'tough as nails' retail investors who have been through the ringer the last few years,... and know I won't be selling anything merely on a 2x or 3x gain from today's levels.
In fact - it is likely I'll keep on adding opportunistically with 'only' a 2x -3x gain back to the levels we were seeing c2013-2014. Have been adding shares aggressively (at least as aggressively as I ever do) during the downslide late 2014-present anyway - so the old cost-average isn't bad relative to current shareprices.
In my 'pie in the sky' scenario for NNVC post revenue generation I would love to see NNVC stay independent (rather than a straight up buy out) and become a steady growing, dividend paying mid-cap pharma.
But suspect that a buyout at some significant premium for shareholders after one of the drug candidates hits the market is the more likely scenario with the relative ages of Dr. Seymour, Dr. Bionuk and others attached to the company. Think they are more likely to want to cash out and enjoy their big-time wealth than to want to build NNVC into some big-time player.
“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM